© 2021 Cryoport, Inc. All Rights Reserved
CYRX: NASDAQ
Cryoport - A Trusted Partner to Life Sciences Companies
Life sciences company focused on providing mission critical, proprietary temperature-controlled supply chain solutions
Capabilities include core competencies to ship, store and deliver biologics in a cryogenic or temperature-controlled state such as:
- CAR-Tand allogeneic therapies
- Human and animal reproductive materials
- Vaccines
Majority of cell therapies need to be shipped at cryogenic temperatures
A leading global manufacturer of cryogenic systems and supplies
One of the largest healthcare specialty logistics providers by revenue
Leading provider of temperature- controlled supply chain solutionsand
productsto the life sciences industry
Cryoport, Inc. (CYRX) operates as a operating holding company with a family of businesses that have separate responsibilities but collectively provide synergistic solutions to the life sciences industry
© 2021 Cryoport, Inc. All Rights Reserved | 2 |
A Global Leader of Temperature-Controlled Supply Chain
Solutions for the Life Sciences Industry
582 | ~44% | 38% | $56.7MM | ||||||||||||||||||||||||||
Active Cell & Gene Therapy | of all Phase III Regenerative | Organic Growth | Q3 2021 Revenue | ||||||||||||||||||||||||||
Clinical Trials Supported (1) | Medicine Clinical Trials Supported (1,4) | in Revenue (2) | |||||||||||||||||||||||||||
8 | 2000+ | 1MM+ | 36 |
Commercial Cell & Gene | Active Global Clients (1) | Shipments (3) | Clinical Trials - COVID-19 Vaccines / |
Therapies Supported (1) | Treatments Supported (1) |
Trusted Provider of Temperature-Controlled Supply Chain Solutions for Temperature-Sensitive Life Sciences Industry
Notes:
1. Data as of 9/30/21 2. Q3 2020-Q3 2021 Year over Year growth of Cryoport Systems and CRYOGENE 3. Total combined shipments of Cryoport Systems and CRYOPDP since inception 4. Derived from 70 Cryoport phase III trials divided by 158 Industry sponsored phase III trials.
© 2021 Cryoport, Inc. All Rights Reserved | 3 |
Attractive High-Growth Regenerative Medicine Market
Driving Expected Demand
Therapies Approved by Modeling Scenario
# new therapies approved by FDA
150
120 | ||||
2027 | ||||
100 | 96 | |||
79 | 2026 | |||
72 | ||||
56 | 2025 | |||
50 | 2024 | |||
2023 | ||||
2022 | ||||
2021 | ||||
0 | 2020 | |||
Lower trial success | Continued market | Faster rate | Faster rate + trial Higher approval rate | |
rate | conditions | of approval | accel. |
Patients Treated per Year in Trials of Commercially Approved Therapies
# of patients treated in-year with C> therapies (000's) in modeled scenarios
600 | CAGR | CAGR |
'20 - "24 | '24 - "27 | |
43% | 32% | |
39% | 30% | |
400 | 32% | 32% |
27% | 33% | |
23% | 30% | |
200 |
0 | |||||||
2020 | 2024 | 2027 | |||||
Lower trial success rate | Continued market conditions | Faster rate of approval | |||||
Faster rate + trial accel. | Higher approval rate | ||||||
Source: Leading third party consulting firm analysis
Notes: Some therapies, such as those focused on treating Hepatitis A and B, will drive higher patient populations; In order to avoid predicting success of individual therapies, we have assumed a standard number of treatable patients per therapy based on average incidents currently in trials. This rate assumes that the total patient population treatable by each therapy does not wholly "replenish" each year, given rare nature of many disease that C & GT targets
© 2021 Cryoport, Inc. All Rights Reserved | 4 |
Dynamic and Expanding TAM
Cell & Gene Therapy Market Expected to Grow 40%+
Regenerative | |||||
Medicine | 1,320 | ~1,195 | $14.1 Bn | 641 | |
1H 2021 | (1) | ||||
Active Global | Gene, Cell & Tissue-Based | Total Global | Active Oncology | ||
Clinical Trials | therapeutic companies globally | Financing Raised | Clinical Trials |
Cell & Gene Therapy Market (2) | ||||
$Bn | The acquisitions of CRYOPDP and MVE Biological Solutions expand | |||
Cryoport's addressable market and provide our customers with end-to-end support | ||||
40 | ||||
$33+ | across the Cell and Gene Therapy value chain. | |||
30 | + | |||
20 | ||||
10 | $4 | Clinical Trial | Cryogenic | |
Logistics | Systems | |||
0 | ||||
2019 | 2024 | |||
Source: (1) The Alliance for Regenerative Medicine (2) | Leading third party consulting analysis |
© 2021 Cryoport, Inc. All Rights Reserved | 5 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Cryoport Inc. published this content on 12 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 January 2022 19:50:08 UTC.